News
ABUS
4.560
-0.87%
-0.040
Arbutus Biopharma Shareholders Approve New 2026 Incentive Plan
TipRanks · 3d ago
Arbutus Biopharma shareholders approve 2026 omnibus share, incentive plan at annual meeting
PUBT · 3d ago
Weekly Report: what happened at ABUS last week (0518-0522)?
Weekly Report · 5d ago
Weekly Report: what happened at ABUS last week (0511-0515)?
Weekly Report · 05/18 10:24
Arbutus Biopharma Q1 revenue surges on Moderna settlement
Reuters · 05/13 11:42
Arbutus Biopharma GAAP EPS of $0.87, revenue of $179.1M
Seeking Alpha · 05/13 11:32
Press Release: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 05/13 11:30
*Arbutus Biopharma 1Q Net $169.7M >ABUS
Dow Jones · 05/13 11:30
*Arbutus Biopharma 1Q Rev $179.1M >ABUS
Dow Jones · 05/13 11:30
*Arbutus Biopharma 1Q EPS 87c >ABUS
Dow Jones · 05/13 11:30
Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early
Seeking Alpha · 05/13 09:41
Arbutus: Q1 Earnings Snapshot
Barchart · 05/13 06:36
Weekly Report: what happened at ABUS last week (0504-0508)?
Weekly Report · 05/11 10:21
Weekly Report: what happened at ABUS last week (0427-0501)?
Weekly Report · 05/04 10:18
UPDATE 2-Moderna tops revenue estimates on stronger international COVID vaccine sales
Reuters · 05/01 10:38
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Reuters · 05/01 10:30
Weekly Report: what happened at ABUS last week (0420-0424)?
Weekly Report · 04/27 10:21
Europe Clears First Flu/COVID Combo Shot From Moderna
Benzinga · 04/21 17:58
Weekly Report: what happened at ABUS last week (0413-0417)?
Weekly Report · 04/20 10:17
Moderna's Quarterly Earnings Preview: What You Need to Know
Barchart · 04/20 05:55
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.